BioAge Labs | Targeting metabolic aging
WEBJun 21, 2024 — Our human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease. Our pipeline programs target key pathways that drive metabolic aging based on novel insights from our platform.
BioAge Labs | In The News - Discovery
WEBFeb 13, 2024 — GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D. © Copyright 2020-2024. All Rights Reserved. The BioAge mission is to extend healthy lifespan by developing treatments that target the molecular causes of human aging.
BioAge Labs | Press Releases - Discovery
WEBMay 16, 2024 — BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide. July 29, 2024.
BioAge Labs | Company
WEBBioAge takes a human-centric, data-driven approach to identify the molecular features of healthy aging and reveal the causes of age-related diseases. By targeting aging with a large and mechanistically diverse portfolio of drugs, we will unlock opportunities to treat or even prevent these diseases in entirely new ways.
BioAge Labs | Events - Discovery
WEBApr 29, 2024 — NASDAQ tower announcement. On the big screen in Times Square, NASDAQ helps us celebrate our $170M Series D to accelerate clinical development for obesity therapeutics. The BioAge mission is to extend healthy lifespan by developing treatments that target the molecular causes of human aging.
BioAge Labs | Pipeline - Discovery
WEBOur lead program, azelaprag, has potential to be a first and best-in-class oral weight loss therapy co-administered with GLP-1 to achieve injectable-like total weight loss and improved body composition.
BioAge Labs | About Aging - Discovery
WEBImpaired immunity increases hospitalization and death from infections and decreases vaccine efficacy in the elderly. Persistent inflammation impairs immunity while worsening chronic diseases— increasing frailty, morbidity, and the risk of premature death.
BioAge Labs | About us - Discovery
WEBOur leadership team has diverse professional experience across the biopharma ecosystem and an established track record of success, involved in 95+ regulatory approvals.
BioAge Labs | BGE-100 - Discovery
WEBAnalysis of BioAge’s proprietary longitudinal human aging cohorts revealed that NLRP3 levels rise with age and are associated with all-cause mortality. BioAge has discovered a family of chemically novel NLRP3 inhibitors. BGE-100 is our most advanced program.
BioAge Labs | Careers - Discovery
WEBBioAge is committed to discovering new drugs for metabolic disease through the lens of aging biology — improving wellness throughout the lifespan and helping people enjoy longer, healthier lives. We are always seeking talented individuals who share our passion to join us in our mission.